Edition:
United States

InspireMD Inc (NSPR.A)

NSPR.A on American Stock Exchange

3.05USD
3:59pm EST
Change (% chg)

$-0.20 (-6.15%)
Prev Close
$3.25
Open
$3.09
Day's High
$3.09
Day's Low
$2.82
Volume
18,740
Avg. Vol
33,519
52-wk High
$23.75
52-wk Low
$1.41

NSPR.A

Chart for NSPR.A

About

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its... (more)
No analyst recommendations are available for NSPR.A.

Overall

Beta: 2.14
Market Cap(Mil.): $4.66
Shares Outstanding(Mil.): 1.43
Dividend: --
Yield (%): --

Financials

  NSPR.A Industry Sector
P/E (TTM): -- 31.03 30.77
EPS (TTM): -22.94 -- --
ROI: -208.54 13.42 15.23
ROE: -334.28 17.11 16.56

BRIEF-InspireMD reports Q3 loss per share $0.86

* InspireMD reports financial results for the third quarter ended September 30, 2016

Nov 14 2016

BRIEF-Inspiremd Inc received approval to commercialize CGuard embolic prevention system

* Inspiremd Inc - received regulatory approval to commercialize cguard embolic prevention system for treatment of carotid artery disease in Russia Source text for Eikon: Further company coverage:

Nov 14 2016

BRIEF-InspireMD names Agustin Gago chief commercial officer

* InspireMD announces appointment of medical device industry veteran Agustin Gago as chief commercial officer Source text for Eikon: Further company coverage:

Oct 26 2016

BRIEF-InspireMD announces 1-for-25 reverse stock split

* Post split, number of outstanding shares will be reduced from approximately 36 million to 1.4 million Source text for Eikon: Further company coverage:

Sep 28 2016

BRIEF-Inspiremd appoints Thomas Kester to Board of Directors

* Inspiremd appoints Thomas Kester To Board of Directors Source text for Eikon: Further company coverage:

Sep 07 2016

BRIEF-Inspiremd non-GAAP net loss $0.16 per share

* Revenue for q2 ended june 30, 2016 was $0.5 million compared to $0.7 million

Aug 09 2016

BRIEF-InspireMD announces pricing of public offering of approximately $14.6 mln

* Each share of series B convertible preferred stock is convertible into 100 shares of common stock at price equal to $0.33 per share

Jun 30 2016

BRIEF-InspireMD amends loan & security agreement with Hercules Capital

* InspireMD announces amendment to loan & security agreement with Hercules Capital

Jun 14 2016

Earnings vs. Estimates